Latest Press Releases

BMO Expands Support for Local Wildfire Relief Efforts in Los Angeles Area

PR Newswire CHICAGO, Jan. 10, 2025 CHICAGO, Jan. 10, 2025 /PRNewswire/ - BMO announced today that it is continuing its support for people and communities affected by the wildfires in the Los Angeles area through donations to two ...

Canary Cure's Game-Changing Obesity Therapy Burns Fat and Protects Muscle

PR Newswire NEW YORK, Jan. 10, 2025 Novel siRNA Therapeutic Demonstrates Significant Fat Loss and Remarkable Lean Body Mass Preservation, and Promises Superior Adherence NEW YORK, Jan. 10, 2025 /PRNewswire/ - Canary Cure Therapeutics, a ...

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

PR Newswire SAN DIEGO, Jan. 10, 2025 SAN DIEGO, Jan. 10, 2025 /PRNewswire/ -- Expert Systems, a hybrid AI enabled drug discovery and development accelerator, announced a significant milestone in a development of Traws Pharma, Inc. 's ...

Gov. Mills' Proposal to Increase Maine's Tobacco Tax Will Protect Kids and Save Lives

PR Newswire WASHINGTON, Jan. 10, 2025 Statement of Yolonda C. Richardson, President & CEO, Campaign for Tobacco-Free Kids WASHINGTON, Jan. 10, 2025 /PRNewswire/ -- The Campaign for Tobacco-Free Kids strongly supports Gov. Janet Mills' ...

Universal Brain Announces Publication of Groundbreaking Depression Research Using Multiple Event-Related Potentials

PR Newswire PALO ALTO, Calif., Jan. 10, 2025 New findings support the company's neuroscience-driven approach to precision psychiatry, offering actionable insights for personalized depression treatment PALO ALTO, Calif., Jan. 10, 2025 ...

Acupuncture Found Effective for Chronic Sciatica Pain in Groundbreaking Study

PR Newswire VANCOUVER, BC, Jan. 10, 2025 A new study in JAMA Internal Medicine confirms acupuncture's effectiveness in relieving chronic sciatica caused by herniated discs. The trial showed significant pain reduction and improved ...

Government of Canada signs bilateral agreement with Saskatchewan to improve access to drugs for rare diseases

Canada NewsWire SASKATOON, SK, Jan. 10, 2025 SASKATOON, SK, Jan. 10, 2025 /CNW/ - In Canada, 1 in 12 people live with a rare disease, and for most people suffering from these diseases, the cost of treatment is unaffordable. Canadians deserve ...

Virion Therapeutics Completes Enrollment of First 2 Cohorts of Phase 1b Chronic Hepatitis B Trial of VRON-0200 For HBV Functional Cure

PR Newswire PHILADELPHIA, Jan. 10, 2025 PHILADELPHIA, Jan. 10, 2025 /PRNewswire/ -- Virion Therapeutics, LLC, a clinical-stage biotechnology company, developing novel T cell-based immunotherapies that utilize first-in-class, checkpoint ...

Woolsey Pharmaceuticals Secures Additional Key U.S. Patent Claims for BRAVYL® (oral fasudil) in Treating ALS, Including Reducing Neurofilament Light (NfL)

PR Newswire NEW YORK, Jan. 10, 2025 NEW YORK, Jan. 10, 2025 /PRNewswire/ -- Woolsey Pharmaceuticals, whose mission is to usher in a new era of neurodegenerative disease treatment, today announced that the U.S. Patent and Trademark Office ...

Verismo Therapeutics Announces First Patient Infused in Phase 1 CELESTIAL-301 Clinical Trial of SynKIR™-310

PR Newswire PHILADELPHIA, Jan. 10, 2025 Clinical-stage CAR T company dosed first patient for Phase 1 trial to evaluate SynKIR™-310, a new drug candidate for relapsed/refractory B cell Non-Hodgkin Lymphomas PHILADELPHIA, Jan. 10, 2025 ...

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

PR Newswire CARLSBAD, Calif., Jan. 10, 2025 -TYRA appoints urologic oncologist, Erik Goluboff, M.D., as SVP, Clinical Development to lead NMIBC- -First patient expected to be dosed in SURF302 in Q2 2025- CARLSBAD, Calif., Jan. 10, ...

Global Competition Launches to Drug 'Undruggable' Cancer Target

PR Newswire DURHAM, N.C., Jan. 10, 2025 DURHAM, N.C., Jan. 10, 2025 /PRNewswire/ -- A new global competition offering over $500,000 in prizes aims to spur drug discovery breakthroughs for the cancer target TBXT. TBXT (also called ...

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis

PR Newswire SAN FRANCISCO, Jan. 10, 2025 SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AD Phase 2b study of rezpegaldesleukin in ...

Mediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

PR Newswire BOSTON, Jan. 10, 2025 Mediar to advance MTX-463 through an IPF Phase 2 trial, with expected initiation in 1H 2025 BOSTON, Jan. 10, 2025 /PRNewswire/ -- Mediar Therapeutics, Inc., a clinical stage biotechnology company ...

The New York Stem Cell Foundation Research Institute Enters Agreement to Accelerate Precision Drug Discovery for Neurodegenerative Disease

PR Newswire NEW YORK, Jan. 10, 2025 Partnership Will Harness NYSCF's Automated Cell Culture Systems and Artificial Intelligence Capabilities to Study Disease at an Unprecedented Cellular Level NEW YORK, Jan. 10, 2025 /PRNewswire/ -- The ...

Inspira™ Preparing Production in Response to Spread of Respiratory Virus in China

PR Newswire RA'ANANA, Israel, Jan. 10, 2025 RA'ANANA, Israel, Jan. 10, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, ...

Ouro Medicines Launches to Define the Future of Treatment for People with Immune-Mediated Diseases

PR Newswire SAN FRANCISCO, Jan. 10, 2025 Ouro will leverage $120 million in funding to develop novel T cell engagers with potential to reset the immune system in patients with chronic immune-mediated diseases Company launches with a ...

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma

PR Newswire SHANGHAI, Jan. 10, 2025 SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy ...

A Step Ahead in Paediatric Care: Manipal Hospital Whitefield Launches Dedicated Paediatric Emergency Bay

PR Newswire BENGALURU, India, Jan. 10, 2025 BENGALURU, India, Jan. 10, 2025 /PRNewswire/ -- Manipal Hospital Whitefield launched a dedicated Paediatric Emergency Bay on Wednesday, 8th Jan 2025 within its emergency department, aiming to ...

Servier Announces Expansion of its Tibsovo (ivosidenib) Development Program Investigating its Safety and Efficacy in Patients Living with IDH1-Mutated Cancers in Both Hematological Malignancies and Solid Tumors

PR Newswire BOSTON, Jan. 9, 2025 BOSTON, Jan. 9, 2025 /PRNewswire/ -- Servier today announced updates to two of its Phase 3 programs evaluating TIBSOVO (ivosidenib tablets) in isocitrate dehydrogenase 1 (IDH1)-mutated cancers. The first ...

SynCardia Systems Receives Decision to Grant First Patent in China for the Emperor Next-Generation Total Artificial Heart

PR Newswire TUCSON, Ariz., Jan. 9, 2025 TUCSON, Ariz., Jan. 9, 2025 /PRNewswire/ -- SynCardia Systems, LLC ("SynCardia", or the "Company"), a Picard Medical, Inc. company, and the global leader in total artificial heart technology, is ...

Crunch Fitness to Open Doors to those Affected by the Los Angeles Wildfires

PR Newswire LOS ANGELES, Jan. 9, 2025 Gyms are open to the community to charge phones, use wifi and take showers LOS ANGELES, Jan. 9, 2025 /PRNewswire/ -- With the wildfires continuing to devastate Los Angeles, Crunch Fitness is ...

Nonprofit CEOs Took the Stage at CES 2025 to Shine Spotlight on How They Use AI and Tech to Treat and Cure Critical Diseases

PR Newswire LAS VEGAS, Jan. 9, 2025 Moore CEO Gretchen Littlefield hosted a Great Minds panel on how big data and tech are being leveraged to progress treatments and cures for cancer, heart disease, Alzheimer's disease and cleft lip and ...

Premature Ejaculation Treatment Market size to increase by USD 1.53 Billion between 2024 to 2029, Market Segmentation by Route Of Administration, Drug Class, Geography , Technavio

PR Newswire NEW YORK, Jan. 9, 2025 NEW YORK, Jan. 9, 2025 /PRNewswire/ -- The global premature ejaculation treatment market size is estimated to grow by USD 1.53 billion from 2025 to 2029, according to Technavio. The market is estimated to ...

BARDA and Partner Therapeutics continue partnership around development of LEUKINE® (sargramostim, rhu GM-CSF) to potentially improve patient care for sepsis

PR Newswire LEXINGTON, Mass., Jan. 9, 2025 LEXINGTON, Mass., Jan. 9, 2025 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) today announced a collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the ...

American Injectables Earns FDA Approval

PR Newswire BROOKSVILLE, Fla., Jan. 9, 2025 BROOKSVILLE, Fla., Jan. 9, 2025 /PRNewswire/ -- American Injectables, a contract development and manufacturing organization (CDMO) specializing in sterile injectables, is proud to announce it has ...

Biofidelity and CellCarta partner to deploy Aspyre® Lung in global clinical trials

PR Newswire CAMBRIDGE, United Kingdom and MONTREAL, Jan. 9, 2025 CAMBRIDGE, United Kingdom and MONTREAL, Jan. 9, 2025 /PRNewswire/ -- Biofidelity, a leader in innovative genomic solutions, and CellCarta, the global contract research ...

Sen-Jam Pharmaceutical Files Groundbreaking Patent for Novel Therapeutic Approach to Address Obesity and Metabolic Disorders

PR Newswire HUNTINGTON, N.Y., Jan. 9, 2025 HUNTINGTON, N.Y., Jan. 9, 2025 /PRNewswire/ -- Sen-Jam Pharmaceutical, a leader in innovative anti-inflammatory care, today announced the submission of a new patent application that introduces a ...

Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis

PR Newswire SPRING HOUSE, Pa., Jan. 9, 2025 Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad population of antibody ...

Hispanic Federation and HabitNu Partner to Combat Rising Rates of Type 2 Diabetes in Hispanic Communities

PR Newswire CHICAGO, Jan. 9, 2025 CHICAGO, Jan. 9, 2025 /PRNewswire/ -- Hispanic Federation, a national nonprofit dedicated to empowering Latino communities, is partnering with HabitNu to bring the CDC-recognized Diabetes Prevention Program ...

Latest Press Releases

Press Releases »

BMO Expands Support for Local Wildfire Relief Efforts in Los Angeles Area

Canary Cure's Game-Changing Obesity Therapy Burns Fat and Protects Muscle

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Gov. Mills' Proposal to Increase Maine's Tobacco Tax Will Protect Kids and Save Lives

Universal Brain Announces Publication of Groundbreaking Depression Research Using Multiple Event-Related Potentials

Acupuncture Found Effective for Chronic Sciatica Pain in Groundbreaking Study

Government of Canada signs bilateral agreement with Saskatchewan to improve access to drugs for rare diseases

Virion Therapeutics Completes Enrollment of First 2 Cohorts of Phase 1b Chronic Hepatitis B Trial of VRON-0200 For HBV Functional Cure

Woolsey Pharmaceuticals Secures Additional Key U.S. Patent Claims for BRAVYL® (oral fasudil) in Treating ALS, Including Reducing Neurofilament Light (NfL)

Verismo Therapeutics Announces First Patient Infused in Phase 1 CELESTIAL-301 Clinical Trial of SynKIR™-310

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

Global Competition Launches to Drug 'Undruggable' Cancer Target

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis

Mediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

The New York Stem Cell Foundation Research Institute Enters Agreement to Accelerate Precision Drug Discovery for Neurodegenerative Disease

Inspira™ Preparing Production in Response to Spread of Respiratory Virus in China

Ouro Medicines Launches to Define the Future of Treatment for People with Immune-Mediated Diseases

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma

A Step Ahead in Paediatric Care: Manipal Hospital Whitefield Launches Dedicated Paediatric Emergency Bay

Servier Announces Expansion of its Tibsovo (ivosidenib) Development Program Investigating its Safety and Efficacy in Patients Living with IDH1-Mutated Cancers in Both Hematological Malignancies and Solid Tumors

SynCardia Systems Receives Decision to Grant First Patent in China for the Emperor Next-Generation Total Artificial Heart

Crunch Fitness to Open Doors to those Affected by the Los Angeles Wildfires

Nonprofit CEOs Took the Stage at CES 2025 to Shine Spotlight on How They Use AI and Tech to Treat and Cure Critical Diseases

Premature Ejaculation Treatment Market size to increase by USD 1.53 Billion between 2024 to 2029, Market Segmentation by Route Of Administration, Drug Class, Geography , Technavio

BARDA and Partner Therapeutics continue partnership around development of LEUKINE® (sargramostim, rhu GM-CSF) to potentially improve patient care for sepsis

American Injectables Earns FDA Approval

Biofidelity and CellCarta partner to deploy Aspyre® Lung in global clinical trials

Sen-Jam Pharmaceutical Files Groundbreaking Patent for Novel Therapeutic Approach to Address Obesity and Metabolic Disorders

Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis

Hispanic Federation and HabitNu Partner to Combat Rising Rates of Type 2 Diabetes in Hispanic Communities

Medindia Newsletters